Circulating MMP9, Vitamin D and Variation in the TIMP-1 Response with VDR Genotype: Mechanisms for Inflammatory Damage in Chronic Disorders?
Overview
Authors
Affiliations
Background: Vitamin-D deficiency and vitamin-D receptor genotype (VDR) are risk factors for several disorders with inflammatory components, including coronary heart disease (CHD) and diabetes, though the mechanisms involved are unclear.
Aim: To examine the hypothesis that vitamin D status modulates the matrix metalloproteinase (MMP) system in a population with a high prevalence of vitamin D deficiency, a situation affecting susceptibility to CHD and diabetes.
Design: Prospective cross-sectional, interventional and embedded studies.
Methods: Circulating MMP2,9, the inhibitor TIMP-1 and C-reactive protein (CRP) were measured during studies of vitamin-D deficiency as a risk factor for type 2 diabetes and CHD in 171 healthy British Bangladeshi adults, free of known diabetes or major illness. Vitamin D status, VDR genotype, body-build, blood pressure, lipid and insulin profiles, glucose tolerance, fibrinogen, PAI-1, folate and homocysteine were measured. Vitamin-D-deficient subjects were re-assessed after 1 years' supplementation. MMP, TIMP-1 and CRP levels were measured in 41 subjects halfway through 5-year follow-up. Independent determinants of circulating concentrations of MMP9, TIMP-1 and CRP were assessed by multiple regression analysis.
Results: Vitamin D status was the sole determinant of circulating MMP9 (inversely) and an independent determinant of CRP (inversely). Determinants of TIMP-1 were MMP9, systolic blood-pressure (directly) and VDR genotype (TaqI). Significant reductions in MMP9 (-68%), TIMP-1 (-38%) and CRP (-23%) concentrations followed vitamin-D supplementation.
Discussion: Vitamin-D insufficiency is associated with increased circulating MMP2,9 and CRP, correctable by supplementation. This finding provides a possible mechanism for tissue damage in chronic inflammatory conditions, including CHD and diabetes.
Grant W, Boucher B Nutrients. 2024; 16(21).
PMID: 39519592 PMC: 11547645. DOI: 10.3390/nu16213759.
Niapour A, Abdollahzadeh M, Ghaheri Fard S, Saadati H Metab Brain Dis. 2024; 39(6):1189-1200.
PMID: 39017968 DOI: 10.1007/s11011-024-01382-z.
Fang J, Han Y, Meng J, Zou H, Hu X, Han Y BMC Endocr Disord. 2024; 24(1):108.
PMID: 38982394 PMC: 11234559. DOI: 10.1186/s12902-024-01640-2.
Salehi Z, Askari M, Jafari A, Ghosn B, Surkan P, Hosseinzadeh-Attar M BMC Public Health. 2024; 24(1):1661.
PMID: 38907196 PMC: 11193220. DOI: 10.1186/s12889-024-18760-y.
Lin Y, Xie C, Zhang Y, Luo F, Gao Q, Li Y J Endocrinol Invest. 2024; 47(11):2745-2755.
PMID: 38733429 DOI: 10.1007/s40618-024-02383-6.